On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Foot Specialist’s Testimonial About Surgery Highlights Non-Opioid Pain Therapy of Endonovo Therapeutics Inc. (ENDV) Device

  • Endonovo Therapeutics is developing a bioceutical device that provides an alternative to the prescription pain pills blamed for hundreds of thousands of deaths in recent years as part of a multinational opioid crisis
  • Endonovo’s proprietary SofPulse® flagship device provides an electrical micro-current to the afflicted part of the body, particularly post-surgery, to minimize a patient’s need for pain relief medication
  • A foot and ankle specialist in Ohio recently used the device following her own tendon surgery and provided a personal testimonial with a professional perspective of the device’s effectiveness in minimizing her pain
  • The SofPulse® device is being evaluated professionally under a plan to be in up to 600 U.S. hospitals by the end of next year

When a foot and ankle medical specialist underwent surgery recently for her own tendon reconstruction need, she presented bioelectronic device maker Endonovo Therapeutics Inc. (OTCQB: ENDV) with a first-person professional perspective of Endonovo’s non-opioid pain relief solution that showcases Endonovo’s revolutionary potential for alleviating an international drug-dependency crisis.

In a home-made video, Dr. Jane Graenber, DPM, of the Foot and Ankle Wellness Center in Delaware, Ohio, attests that Endonovo’s SofPulse® electroceutical device has helped her to remain generally pain-free a day after the tendon surgery, such that she says she has only used three doses of Tylenol for relief (no prescription pain pills) during the interim since her procedure (http://ibn.fm/H2n5X).

“This device is putting out a micro-current to my surgical area every two hours… And it’s taken care of the pain, and I’m sitting here very comfortably,” Graenber states in the video. “At our practice we may be starting to include this post-operatively as an option to reduce pain. This was a pretty big surgery and I’m really very comfortable. So I’m giving credit to a good surgeon but also a new device that may revolutionize pain (treatment) after surgery.”

Endonovo announced its initial strategy to begin a national rollout of the SofPulse® on June 13 with plans to be in the evaluation stage at 600 U.S. hospitals through the end of next year (http://ibn.fm/P0w4a). Graenber identifies the video’s date as August 3, countering a time stamp at the bottom of the video that says it was recorded in January 2015.

The proliferation of opioids for pain relief following medical procedures during the past two decades has generated worldwide concerns about the prescription pills’ apparent role in creating patients’ ensuing drug addictions – addictions that have been cited in the deaths of hundreds of thousands of people. The Centers for Disease Control and Prevention states that as of 2017, its statistics showed an average of 130 Americans were dying every day from an opioid overdose (http://ibn.fm/4e49T).

The concerns about opioid abuse have sparked a multi-national sea change in attitudes regarding marijuana use as a medical therapy, although the cannabis plant’s products remain controversial with many governmental regulators. Endonovo’s SofPulse® provides a non-drug alternative to treating pain relief, entirely bypassing concerns about potential substance abuse and harmful side effects.

Furthermore, a recent scientific study of patient outcomes is countering the popularly held idea that marijuana reform is reducing the number of opioid-related deaths. The study published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) in June found that states where cannabis legislation has eased access to medical marijuana as an alternative to opioids have actually seen an increase in opioid-related deaths in recent years, rather than a decrease (http://ibn.fm/0BsyR).

“Cannabinoids have demonstrated therapeutic benefits, but reducing population-level opioid overdose mortality does not appear to be among them,” the study states.

Endonovo’s therapy platform has received clearance for the palliative treatment of post-operative pain and swelling from the U.S. Federal Drug Administration, insurance coverage for chronic wound treatment from the national Centers for Medicare and Medicaid Services, and a CE-mark certification that denotes conformity with European Economic Area health and environmental standards related to wound, pain and edema treatment.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered